When applied to pretreatment transcriptomic data from patients with melanoma subsequently treated with ICIs, TIDE outperformed other predictive biomarkers tested, including PD-L1 expression, TMB, and IFN-γ signature. This evidence concerns the gene CD274 and melanoma.